Use of b cell depleting agents for the treatment of rheumatic heart disease

Rheumatic heart disease (RHD) ranks as one of the most serious cardiovascular scourges of the past century and remains a force to be reckoned with in the developing world. Using the B-HOT panel, developed in part by our team, and based on heatmap analysis, we show two distinct transcriptomic profiles between inflammatory burden region of RHD valves patients (n=13) and control valves (without lesions, n=10). Our differential gene expression analysis between those 2 groups show several genes overexpressed in RHD group compared to control valves. Interestingly, and as potential therapeutic targets, genes related to CD20 (MS4A1, MS4A2) are among genes that are differentially expressed. Taken together, these results suggest a potential role for CD20 in inflammatory responses of RHD valves lesions. Anti-CD20 antibodies, like Rituximab (CD20), would be potential therapeutic molecules to be used on RHD patients.

Patent Application number: European Procedure (Patents) (EPA) - 01 Juin 2021 - 21 305 727.6
Inventors:
JOUVEN XavierLOUPY Alexandre
Publications:
null

Reference:

BIO21254-T1

    Business Developper
    contact
    Aymeric Empereur
    Business Developer
    Patent filling date: null
    Rare disease: No
    Second indication: No

    You might also be interested in